Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)
Confident Investing Starts Here:
Exact Sciences (EXAS)
In a report issued on June 2, Brandon Couillard from Wells Fargo maintained a Buy rating on Exact Sciences, with a price target of $68.00. The company's shares closed last Tuesday at $54.84.
According to TipRanks.com, Couillard is a 5-star analyst with an average return of 14.1% and a 59.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and Myriad Genetics.
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $69.94.
In a report issued on June 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences, with a price target of $46.00. The company's shares closed last Tuesday at $10.03.
According to TipRanks.com, Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.0% and a 33.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics.
Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $27.88, representing a 203.4% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $14.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 hours ago
- Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2025 Biotech Back to School Conference Date: Wednesday, September 3 rd, 2025 Location: Boston, MA Format: Fireside chat & 1x1 meetings Time: 11:15 a.m. ET H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:30 a.m. ET Live webcasts of the fireside chats will be available by visiting the 'Investors & Media' section of the Arcus Biosciences website at Replays will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit
Business Insider
19 hours ago
- Business Insider
Analysts Offer Insights on Consumer Goods Companies: a2 Milk Company (OtherACOPF), Waldencast (WALD) and China Resources Beer (Holdings) Co (OtherCRHKF)
Companies in the Consumer Goods sector have received a lot of coverage today as analysts weigh in on a2 Milk Company (ACOPF – Research Report), Waldencast (WALD – Research Report) and China Resources Beer (Holdings) Co (CRHKF – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. a2 Milk Company (ACOPF) In a report released today, Sam Teeger from Citi upgraded a2 Milk Company to Buy, with a price target of A$9.29. The company's shares closed last Tuesday at $5.61. According to Teeger is a 3-star analyst with an average return of 3.1% and a 42.7% success rate. Teeger covers the NA sector, focusing on stocks such as Domino's Pizza Enterprises Limited, Temple & Webster Group Ltd, and ARB Corporation. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for a2 Milk Company with a $5.49 average price target, a -0.2% downside from current levels. In a report issued on August 5, UBS also maintained a Buy rating on the stock. Waldencast (WALD) In a report released yesterday, Jonna Kim from TD Cowen maintained a Hold rating on Waldencast, with a price target of $2.00. The company's shares closed last Tuesday at $1.80. According to Kim is a 4-star analyst with an average return of 15.4% and a 38.9% success rate. Kim covers the NA sector, focusing on stocks such as Victoria's Secret, Bath & Body Works, and Olaplex Holdings. Currently, the analyst consensus on Waldencast is a Moderate Buy with an average price target of $3.23, implying a 65.6% upside from current levels. In a report released yesterday, Raymond James also reiterated a Hold rating on the stock. China Resources Beer (Holdings) Co (CRHKF) In a report released today, Clement Xu from DBS maintained a Buy rating on China Resources Beer (Holdings) Co, with a price target of HK$35.60. The company's shares closed last Tuesday at $3.42. According to Xu is ranked #2592 out of 9989 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for China Resources Beer (Holdings) Co with a $4.56 average price target.
Business Insider
19 hours ago
- Business Insider
Analysts Are Bullish on Top Technology Stocks: Sunny Optical Technology (Group) Co (SNPTF), Lam Research (LRCX)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Sunny Optical Technology (Group) Co (SNPTF – Research Report) and Lam Research (LRCX – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Sunny Optical Technology (Group) Co (SNPTF) DBS analyst Jim Hin Kwong Au maintained a Buy rating on Sunny Optical Technology (Group) Co today and set a price target of HK$110.00. The company's shares closed last Tuesday at $9.87. According to Au is a 5-star analyst with an average return of 18.4% and a 69.7% success rate. Au covers the Technology sector, focusing on stocks such as BYD Electronic (International) Co, AAC Technologies Holdings, and ASM Pacific Technology. Currently, the analyst consensus on Sunny Optical Technology (Group) Co is a Strong Buy with an average price target of $12.17. Lam Research (LRCX) In a report released yesterday, Vijay Rakesh from Mizuho Securities reiterated a Buy rating on Lam Research, with a price target of $120.00. The company's shares closed last Tuesday at $100.33. According to Rakesh is a 5-star analyst with an average return of 21.5% and a 59.8% success rate. Rakesh covers the Technology sector, focusing on stocks such as Credo Technology Group Holding Ltd, Advanced Micro Devices, and ARM Holdings PLC ADR. Currently, the analyst consensus on Lam Research is a Strong Buy with an average price target of $112.64, a 14.0% upside from current levels. In a report issued on August 14, Erste Group also initiated coverage with a Buy rating on the stock.
